[go: up one dir, main page]

WO2008136511A1 - Agent thérapeutique pour neuropathie diabétique - Google Patents

Agent thérapeutique pour neuropathie diabétique Download PDF

Info

Publication number
WO2008136511A1
WO2008136511A1 PCT/JP2008/058420 JP2008058420W WO2008136511A1 WO 2008136511 A1 WO2008136511 A1 WO 2008136511A1 JP 2008058420 W JP2008058420 W JP 2008058420W WO 2008136511 A1 WO2008136511 A1 WO 2008136511A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic neuropathy
therapeutic agent
disclosed
agonist
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/058420
Other languages
English (en)
Japanese (ja)
Inventor
Masamitsu Nakazato
Itaru Kyoraku
Kazutaka Shiomi
Yujiro Hayashi
Kenji Kangawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miyazaki NUC
National Cerebral and Cardiovascular Center
Asubio Pharma Co Ltd
Original Assignee
University of Miyazaki NUC
National Cerebral and Cardiovascular Center
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miyazaki NUC, National Cerebral and Cardiovascular Center, Asubio Pharma Co Ltd filed Critical University of Miyazaki NUC
Publication of WO2008136511A1 publication Critical patent/WO2008136511A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un agent thérapeutique pour neuropathie diabétique qui comprend un agoniste d'un récepteur du facteur de stimulation de la sécrétion de l'hormone de croissance ou l'un de ses sels acceptables sur le plan pharmaceutique en tant qu'ingrédient actif. L'invention concerne également un procédé permettant de traiter une neuropathie diabétique qui comprend le fait d'administrer la substance à un individu.
PCT/JP2008/058420 2007-05-07 2008-05-02 Agent thérapeutique pour neuropathie diabétique Ceased WO2008136511A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-122897 2007-05-07
JP2007122897 2007-05-07

Publications (1)

Publication Number Publication Date
WO2008136511A1 true WO2008136511A1 (fr) 2008-11-13

Family

ID=39943615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058420 Ceased WO2008136511A1 (fr) 2007-05-07 2008-05-02 Agent thérapeutique pour neuropathie diabétique

Country Status (1)

Country Link
WO (1) WO2008136511A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087102A1 (fr) * 2010-01-15 2011-07-21 国立大学法人宮崎大学 Agent thérapeutique pour encourager la récupération d'un animal sous traitement médical

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041901A2 (fr) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Agents therapeutiques utilisant les agonistes de somatostatine
WO2006033341A1 (fr) * 2004-09-22 2006-03-30 Kureha Corporation Agent therapeutique ou prophylactique pour la neuropathie diabetique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041901A2 (fr) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Agents therapeutiques utilisant les agonistes de somatostatine
WO2006033341A1 (fr) * 2004-09-22 2006-03-30 Kureha Corporation Agent therapeutique ou prophylactique pour la neuropathie diabetique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IRAKO T. ET AL.: "Ghrelin wa Shinseiji Tonyobyo Model Rat no Tonyobyo Hassho o Soshi suru", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 49, no. SUPPL. 1, 25 April 2006 (2006-04-25), pages S211 *
NAKAZATO N.: "Nanchisei Neuropathy no Byotai ni Motozuku Shinki Chiryoho no Kaihatsu Tonyobyosei Neuropathy ni Taisuru Shinki Peptide Ghrelin o Mochiita Aratana Chiryoho no Kaihatsu", NANCHISEI NEUROPATHY NO BYOTAI NI MOTOZUKU SHINKI CHIRYOHO NO KAIHATSU HEISEI 16-18 NENDO SOKATSU KENKYU HOKOKUSHO, 2006, pages 24 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087102A1 (fr) * 2010-01-15 2011-07-21 国立大学法人宮崎大学 Agent thérapeutique pour encourager la récupération d'un animal sous traitement médical
US9078868B2 (en) 2010-01-15 2015-07-14 University Of Miyazaki Therapeutic agent for accelerating recovery of animal under medical treatment

Similar Documents

Publication Publication Date Title
WO2010122980A8 (fr) Nouvel agoniste du récepteur ss de l'hormone thyroïdienne
EP2371853A3 (fr) Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
WO2008096775A1 (fr) Agent thérapeutique pour la douleur
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20074628L (no) Formuleringer av octreotid med kontrollert frigjoring
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
BR112015010314A8 (pt) composto ou sais farmaceuticamente aceitáveis ou isômeros dos mesmos, composição farmacêutica, secretagogo de insulina ou agente hipoglicêmico, agonista do receptor gpr40, e, método para tratar doenças ou distúrbios
WO2005115361A3 (fr) Modulateurs des recepteurs d'androgenes et methodes de traitement de maladies utilisant ceux-ci
WO2008027854A3 (fr) Compositions pharmaceutiques à hormone de croissance humaine pour délivrance par voie orale
WO2006086488A3 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2010107807A3 (fr) Composés destinés au traitement de l'inflammation et de la douleur
WO2010053861A3 (fr) Amides biologiquement actifs
WO2010138770A3 (fr) Méthodes d'administration et formulations destinées au traitement de tissu adipeux régional
WO2008144269A3 (fr) Methodes d'utilisation d'antagonistes de vasopressine avec des agents chimiotherapeutiques a base d'anthracycline visant a reduire la cardiotoxicite et/ou ameliorer la survie
EP2316420A8 (fr) Procédé pour réduire la douleur
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2008100448A3 (fr) Procédé de traitement des troubles prolifératifs cellulaires utilisant un sécrétagogue d'hormone de croissance
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
WO2006108176A3 (fr) Agonistes et antagonistes du recepteur beta 2 adrenergique et modulation de cicatrisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08752325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP